What is Taysha Gene Therapies, Inc.'s market cap?

Taysha Gene Therapies, Inc. (TSHA) has a market capitalization of $1.6B and trades on NASDAQ.

What is Taysha Gene Therapies, Inc.'s revenue and profitability?

Taysha Gene Therapies, Inc. generated $7.5M in trailing twelve-month revenue with a net loss of $129.9M, representing a net margin of -1738.4%, with free cash flow of -$112.3M. These figures are based on the Q1 2026 filing.

Who are Taysha Gene Therapies, Inc.'s competitors?

Taysha Gene Therapies, Inc.'s key competitors include Biogen Inc., Ionis Pharmaceuticals, Inc., Acadia Pharmaceuticals Inc., and others. These companies compete in similar markets and product categories.

Who does Taysha Gene Therapies, Inc. partner with?

Taysha Gene Therapies, Inc.'s notable partners include The University of Texas Southwestern Medical Center, Abeona Therapeutics Inc., Audentes Therapeutics, Inc. (Astellas Gene Therapy), and others.

Where is Taysha Gene Therapies, Inc. headquartered?

Taysha Gene Therapies, Inc. is headquartered in United States of America and employs approximately 52 people. It has been publicly traded since 2020.

Taysha Gene Therapies, Inc.

TSHA

Taysha Gene Therapies is a clinical-stage biotechnology company dedicated to developing AAV-based gene therapies for severe monogenic diseases of the central nervous system.

Market cap

$1.59B+122%

Revenue$7.5M+3.4%

Net income-$129.9M-49.7%

Free cash flow-$112.3M-33.6%

EPS (diluted)-$0.38-11.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue-EPS-$0.12Miss by $0.02

Read the full report

Next report

Aug 11, 2026 (In 1 week)

Revenue estimate$618.2K

EPS estimate-$0.11

Financials

Q1 2026

Income statement

See full

Revenue--100%

Operating income-$43.5M-103%

Net income-$42.4M-97.0%

EPS (diluted)-$0.12-50.0%

Balance sheet

See full

Cash & equivalents$276.6M+137%

Total debt$68.6M+11.2%

Total equity$211.9M+285%

Total assets$300.4M+117%

Cash flow

See full

Operating cash flow-$40.9M-85.6%

CapEx$24.0K-93.7%

Free cash flow-$40.9M-82.6%

Valuation & ratios

Valuation

See full

Market cap$1.59B+122%

Enterprise value$1.38B+211%

P/S213.1×+127×

Profitability

See full

Operating margin-1,774.4%+1,437pp

Net margin-1,738.4%+1,407pp

FCF margin-1,503.6%+621pp

Returns & leverage

See full

Return on equity-97.3%-27.3pp

Debt / equity0.3×-0.8×

Current ratio14×+8.7×

Competitors

By market cap

Biogen$29.5B+56.0%

Ionis Pharmaceuticals$9.2B+41.1%

Acadia Pharmaceuticals$4.3B+14.8%

Ultragenyx Pharmaceutical$2.6B+1.5%

uniQure$2.6B+220%

Taysha Gene Therapies, Inc.$1.6B+128%

Tenaya Therapeutics, Inc.$167.0M+31.6%

PAS

Passage Bio, Inc.$14.8M-32.5%

By revenue growth

Ionis Pharmaceuticals+47.5%

Ultragenyx Pharmaceutical+13.5%

Acadia Pharmaceuticals+9.9%

Taysha Gene Therapies, Inc.+3.4%

Biogen+1.2%

uniQure-10.4%

By net margin

Acadia Pharmaceuticals34.3%+11.3pp

Biogen14.3%-0.8pp

Ionis Pharmaceuticals-30.9%+33.0pp

Ultragenyx Pharmaceutical-90.92%+2.2pp

uniQure-1,154.42%-77.4pp

Taysha Gene Therapies, Inc.-1,738.4%-537pp

Profile

Taysha Gene Therapies is a clinical-stage biotechnology company dedicated to developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. The company's core value proposition lies in its use of the AAV9 capsid and proprietary miRARE technology to address the genetic root causes of rare neurodevelopmental disorders. Its lead program, TSHA-102, is currently in pivotal clinical development for the treatment of Rett syndrome.

Competitive position

A clinical-stage developer focusing on first-in-class treatments for Rett syndrome with specialized regulatory designations including Breakthrough Therapy and RMAT.

GeographiesUnited States, Canada, United Kingdom, European Union

Customer segmentsRare disease patients, Pediatric patients

Business modelBiopharmaceutical R&D

SuppliersAcademic research institutions, AAV9 capsid technology providers, Contract manufacturing organizations (CMOs), Clinical trial sites

CustomersSpecialty pharmacies, Hospitals, Government healthcare programs, Private insurers

CountryUnited States of America

Listed2020

Employees52.0

CEOSean Nolan

SectorHealthcare

IndustryBiotechnology

Websitetayshagtx.com

FilingsSEC EDGAR

Ask your AI about Taysha Gene Therapies, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Taysha Gene Therapies, Inc.'s market cap?: Taysha Gene Therapies, Inc. (TSHA) has a market capitalization of $1.6B and trades on NASDAQ.
What is Taysha Gene Therapies, Inc.'s revenue and profitability?: Taysha Gene Therapies, Inc. generated $7.5M in trailing twelve-month revenue with a net loss of $129.9M, representing a net margin of -1738.4%, with free cash flow of -$112.3M. These figures are based on the Q1 2026 filing.
Who are Taysha Gene Therapies, Inc.'s competitors?: Taysha Gene Therapies, Inc.'s key competitors include Biogen Inc., Ionis Pharmaceuticals, Inc., Acadia Pharmaceuticals Inc., and others. These companies compete in similar markets and product categories.
Who does Taysha Gene Therapies, Inc. partner with?: Taysha Gene Therapies, Inc.'s notable partners include The University of Texas Southwestern Medical Center, Abeona Therapeutics Inc., Audentes Therapeutics, Inc. (Astellas Gene Therapy), and others.
Where is Taysha Gene Therapies, Inc. headquartered?: Taysha Gene Therapies, Inc. is headquartered in United States of America and employs approximately 52 people. It has been publicly traded since 2020.